Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group
- PMID: 27185849
- PMCID: PMC4981978
- DOI: 10.1200/JCO.2015.65.3469
Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group
Abstract
Purpose: Children's Oncology Group study AHOD03P1 was designed to determine whether excellent outcomes can be maintained for patients with low-risk, pediatric lymphocyte-predominant Hodgkin lymphoma (LPHL) with a strategy of resection alone or minimal chemotherapy.
Patients and methods: Patients with stage IA LPHL in a single node that was completely resected were observed without further therapy; recurrences were treated with three cycles of doxorubicin/vincristine/prednisone/cyclophosphamide (AV-PC). Patients with unresected stage IA or stage IIA LPHL were treated with three cycles of AV-PC. Patients with less than a complete response (CR) to AV-PC received 21-Gy involved-field radiation therapy (IFRT).
Results: A total of 183 eligible patients were enrolled; 178 were evaluable. Of these, 52 patients underwent complete resection of a single node. There were 13 relapses at a median of 11.5 months; 5-year event-free survival (EFS) was 77% (range, 62% to 87%). A total of 135 patients received AV-PC; 126 were treated at diagnosis and nine at relapse after surgery alone. Eleven patients receiving AV-PC had less than CR and received IFRT. Fourteen first events occurred among 135 patients (12 relapses and two second malignancies). Two relapses occurred in patients who had received IFRT. Five-year EFS was 88.8% (95% CI, 81.8% to 93.2%). Five-year EFS for the entire cohort was 85.5% (95% CI, 79.2% to 90.1%); overall survival was 100%.
Conclusion: Some 75% of highly selected pediatric patients with LPHL may be spared chemotherapy after surgical resection alone. Pediatric LPHL has excellent EFS with chemotherapy that is less intensive than standard regimens; > 90% of patients can avoid radiation therapy. The salvage rate for the few relapses is high, with 100% survival overall.
© 2016 by American Society of Clinical Oncology.
Conflict of interest statement
Authors’ disclosures of potential conflicts of interest are found in the article online at
Figures
Similar articles
-
Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: A report from the Children's Oncology Group.Pediatr Blood Cancer. 2018 Dec;65(12):e27375. doi: 10.1002/pbc.27375. Epub 2018 Sep 14. Pediatr Blood Cancer. 2018. PMID: 30277639 Free PMC article. Clinical Trial.
-
Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group.Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):60-6. doi: 10.1016/j.ijrobp.2014.10.042. Epub 2014 Dec 24. Int J Radiat Oncol Biol Phys. 2015. PMID: 25542311 Free PMC article. Clinical Trial.
-
Impact of low-dose involved-field radiation therapy on pediatric patients with lymphocyte-predominant Hodgkin lymphoma treated with chemotherapy: a report from the Children's Oncology Group.Pediatr Blood Cancer. 2012 Dec 15;59(7):1284-9. doi: 10.1002/pbc.24258. Epub 2012 Jul 27. Pediatr Blood Cancer. 2012. PMID: 22847767 Free PMC article. Clinical Trial.
-
Current approaches to the management of pediatric Hodgkin lymphoma.Paediatr Drugs. 2010 Apr 1;12(2):85-98. doi: 10.2165/11316170-000000000-00000. Paediatr Drugs. 2010. PMID: 20218745 Review.
-
Treatment of pediatric hodgkin lymphoma.Curr Treat Options Oncol. 2008 Feb;9(1):81-94. doi: 10.1007/s11864-008-0058-0. Epub 2008 May 7. Curr Treat Options Oncol. 2008. PMID: 18461462 Review.
Cited by
-
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.Blood. 2019 May 16;133(20):2121-2129. doi: 10.1182/blood-2018-10-877761. Epub 2019 Feb 15. Blood. 2019. PMID: 30770396 Free PMC article.
-
Efficacy of Surgery in Patients with Stage I Primary Parotid Gland Lymphoma: A Population-Based Study.J Oncol. 2022 Nov 28;2022:4977600. doi: 10.1155/2022/4977600. eCollection 2022. J Oncol. 2022. PMID: 36478747 Free PMC article.
-
Surgeon Concordance in the Assessment of Resectability for Stage IA Nodular Lymphocyte Predominant Hodgkin Lymphoma.J Pediatr Hematol Oncol. 2018 Apr;40(3):246-247. doi: 10.1097/MPH.0000000000001107. J Pediatr Hematol Oncol. 2018. PMID: 29401099 Free PMC article. No abstract available.
-
Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. Pediatr Blood Cancer. 2023. PMID: 37505794 Free PMC article.
-
Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma.J Taibah Univ Med Sci. 2020 Sep 15;15(6):554-556. doi: 10.1016/j.jtumed.2020.08.004. eCollection 2020 Dec. J Taibah Univ Med Sci. 2020. PMID: 33318747 Free PMC article.
References
-
- Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin’s disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453–458. - PubMed
-
- Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin’s disease. N Engl J Med. 1997;337:459–466. - PubMed
-
- Harris NL. Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: Differential diagnosis and biological implications. Mod Pathol. 2013;26:S57–S70. (suppl 1) - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical